Provexis has developed and licensed its first major product: Fruitflow® a patented, scientifically-proven tomato extract which inhibits platelet aggregation, a known cause of heart attack, stroke and venous thrombosis. The syrup and powder versions of Fruitflow® are GRAS (Generally Regarded as Safe) in the US and are not regarded as Novel Foods in the EU, clearing them for wide use in foods, beverages and supplements.


In June 2010 it was announced that the company had entered into a long-term Alliance Agreement with DSM Nutritional Products to commercialise Fruitflow®. The Alliance is seeing the partners collaborate to develop Fruitflow® in all major global markets, through an effective commercialisation of current formats and pioneering new and significant applications. DSM is responsible for: manufacturing; marketing; and selling via its substantial sales force. Provexis is responsible for contributing scientific expertise necessary for successful commercialisation. Profits from the Alliance are being shared by the parties on an agreed basis, linked to various performance milestones.

More recently, Fruitflow® was a key ingredient in ‘all natural’ Thromboflow, a product created by Dr Wolz in Germany which won ‘Reform product of the year 2013’. More details on this exciting milestone can be found at:

Share price information

Trade time
Latest price
Price change